Sini Li

835 total citations
57 papers, 517 citations indexed

About

Sini Li is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Sini Li has authored 57 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 9 papers in Immunology. Recurrent topics in Sini Li's work include Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Economic and Financial Impacts of Cancer (7 papers). Sini Li is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Economic and Financial Impacts of Cancer (7 papers). Sini Li collaborates with scholars based in China, Hong Kong and United Kingdom. Sini Li's co-authors include Xiaomin Wan, Liubao Peng, Jie Wang, Lihui Liu, Chongqing Tan, Xiaohui Zeng, Yamin Li, Jianhe Li, Pei Xue and Lidan Yi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Sini Li

51 papers receiving 514 citations

Peers

Sini Li
B. Mayer Grob United States
Krisztina Bogos Hungary
Xiuling Zhou China
Penelope Fisher United States
Yiwu Huang United States
R Weichselbaum United States
Elizabeth Ahern Australia
Iryna Kuchuk Canada
Letizia Gianoncelli Italy
Catharina Bartmann Germany
B. Mayer Grob United States
Sini Li
Citations per year, relative to Sini Li Sini Li (= 1×) peers B. Mayer Grob

Countries citing papers authored by Sini Li

Since Specialization
Citations

This map shows the geographic impact of Sini Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sini Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sini Li more than expected).

Fields of papers citing papers by Sini Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sini Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sini Li. The network helps show where Sini Li may publish in the future.

Co-authorship network of co-authors of Sini Li

This figure shows the co-authorship network connecting the top 25 collaborators of Sini Li. A scholar is included among the top collaborators of Sini Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sini Li. Sini Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Sini, Wai Tong Chien, Stanley Kam Ki Lam, Yuen Yu Chong, & Andrew T. Gloster. (2024). Psychometric Properties of the Chinese Version of the Psy-Flex Among Parents of Children with Autism Spectrum Disorder. Journal of Autism and Developmental Disorders. 56(3). 1185–1199. 2 indexed citations
2.
Ma, Jing, Sini Li, Chongqing Tan, et al.. (2024). Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study. PharmacoEconomics. 42(12). 1345–1357. 1 indexed citations
3.
Wu, Mei-Yu, Jing Ma, Xuehong Wang, et al.. (2024). Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study. Clinical and Molecular Hepatology. 31(2). 394–408. 2 indexed citations
4.
Li, Sini, Yan Qu, Lihui Liu, et al.. (2023). Tumour‐derived exosomes in liver metastasis: A Pandora's box. Cell Proliferation. 56(10). e13452–e13452. 15 indexed citations
5.
Ye, Peng, Liting Wang, Liubao Peng, et al.. (2023). Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States. Clinical Therapeutics. 45(10). 965–972. 3 indexed citations
6.
Liu, Jianghong, et al.. (2023). Social Connection and Lifestyle Factors Associated With Happiness in Urban Older Adults in China: A Cross-Sectional Study With a Community Sample. Research in Gerontological Nursing. 16(3). 147–160. 2 indexed citations
7.
Li, Sini, Lihui Liu, Yan Qu, et al.. (2023). Comprehensive Analyses and Immunophenotyping of LIM Domain Family Genes in Patients with Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences. 24(5). 4524–4524. 1 indexed citations
8.
9.
Liu, Lihui, Sini Li, Yan Qu, et al.. (2023). Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. Cell Reports Medicine. 4(10). 101206–101206. 30 indexed citations
10.
11.
Wang, Liting, Peng Ye, Xiaomin Wan, et al.. (2023). First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. PLoS ONE. 18(4). e0279786–e0279786. 6 indexed citations
12.
13.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2022). Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers in Pharmacology. 13. 778505–778505. 19 indexed citations
14.
Liu, Lihui, Hua Bai, Chao Wang, et al.. (2021). Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. Journal of Thoracic Oncology. 16(7). 1099–1117. 92 indexed citations
15.
Li, Sini, Jianhe Li, Liubao Peng, et al.. (2021). First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis. Clinical Therapeutics. 43(7). 1253–1264.e5. 3 indexed citations
16.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2021). Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy. Frontiers in Oncology. 11. 743765–743765. 4 indexed citations
17.
Li, Sini, Jianhe Li, Liubao Peng, Yamin Li, & Xiaomin Wan. (2021). Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Frontiers in Oncology. 11. 684073–684073. 10 indexed citations
18.
Tan, Chongqing, Xia Luo, Sini Li, et al.. (2021). Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis. Clinical Rheumatology. 41(1). 63–73. 4 indexed citations
19.
Li, Sini, Liubao Peng, Chongqing Tan, et al.. (2020). Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PLoS ONE. 15(5). e0232240–e0232240. 22 indexed citations
20.
Li, Sini, et al.. (2009). Comparative Enzyme Immunoassay of Matrix Metalloproteinases-2, -7, -9 and Their Tissue Inhibitor-2 in Tumors and Plasma of Patients with Gastric Cancer. Bulletin of Experimental Biology and Medicine. 148(6). 899–902. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. Mayer Grob Breakdown of academic impact, for papers by Krisztina Bogos Breakdown of academic impact, for papers by Xiuling Zhou Breakdown of academic impact, for papers by Penelope Fisher Breakdown of academic impact, for papers by Yiwu Huang Breakdown of academic impact, for papers by R Weichselbaum Breakdown of academic impact, for papers by Elizabeth Ahern Breakdown of academic impact, for papers by Iryna Kuchuk Breakdown of academic impact, for papers by Letizia Gianoncelli Breakdown of academic impact, for papers by Catharina Bartmann
Rankless by CCL
2026